David A. Siegel Cassava Sciences Inc Transaction History
Two Sigma Advisers, LP
- $46.1 Billion
- Q2 2025
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Cassava Sciences Inc stock. As of the latest transaction made, Two Sigma Advisers, LP holds 983,600 shares of SAVA stock, worth $2.28 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
983,600
Previous 908,600
8.25%
Holding current value
$2.28 Million
Previous $1.36 Million
30.69%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding SAVA
# of Institutions
131Shares Held
14.2MCall Options Held
963KPut Options Held
866K-
Black Rock Inc. New York, NY3.22MShares$7.47 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.17MShares$5.03 Million0.0% of portfolio
-
Jpmorgan Chase & CO New York, NY790KShares$1.83 Million0.0% of portfolio
-
Goldman Sachs Group Inc New York, NY613KShares$1.42 Million0.0% of portfolio
-
Two Sigma Investments, LP New York, NY527KShares$1.22 Million0.0% of portfolio
About CASSAVA SCIENCES INC
- Ticker SAVA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 40,097,900
- Market Cap $93M
- Description
- Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...